Penetration of Ceftaroline Into Cerebrospinal Fluid(CSF)
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Ceftaroline is a piece of new cephalosporin very active on resistant staphylococci in
methicillin (SEMR: Staphylococcus Epidermidis Resistant in Methicillin, SMAR: Staphylococcus
Aureus Resistant in Methicillin)and/or in vancomycin ; Ceftaroline is also very active on
pneumococci resistant in penicillin and/or 3rd generation of cephalosporins.
Ceftaroline was approved by the European Medicines Agency for the treatment of complicated
skin and soft tissue infections and community-acquired pneumonia.
Scientific literature describes a good efficiency in septicemy and/or SAMR endocarditis.
Besides, a study on animal shows the efficiency of ceftaroline in meningeal infections with
gram-negative Bacilli.
The rationale of this study is based on the antibacterial spectra of ceftaroline that could
be used for the antibacterial treatment (curative and prophylactic) of CSF shunt associated
infections.
To validate this hypothesis, it is necessary to evaluate the concentration of ceftaroline in
meningeal compartment after treatment.